4.5 Review

Parasitic worm therapy for allergy: Is this incongruous or avant-garde medicine?

Journal

CLINICAL AND EXPERIMENTAL ALLERGY
Volume 42, Issue 4, Pages 505-512

Publisher

WILEY
DOI: 10.1111/j.1365-2222.2011.03911.x

Keywords

allergic rhinitis; clinical trial; helminth; hookworm; immunotherapy; Necator americanus (hookworm) RCT (randomized controlled trial); regulatory T cell; T helper 2 (Th2); Trichuris suis ova (TSO); worm therapy

Funding

  1. Wellcome Trust
  2. Broad Foundation
  3. MS Society
  4. University of Nottingham
  5. Clinical Trials Unit
  6. School of Pharmacy Research Committee

Ask authors/readers for more resources

Helminth (worm) therapy has already been used in clinical trials associated with allergy. These were generally small scale, safety orientated trials of short duration, justified by epidemiological and experimental data indicating potentially beneficial immune modulation by some parasites. However, parasites by definition are disadvantageous to their hosts, and helminth infection in particular almost invariably induces an allergic phenotype, rendering this somewhat paradoxical therapeutic approach for allergy open to scrutiny. Is parasitic worm therapy for allergy incongruous medicine, or avant-garde medicine? In the present article, we assess the strength of evidence supporting the use of helminth therapy for allergy and critically appraise the trials already completed. Then, should this approach prove successful, we suggest strategies to improve the delivery of helminth therapy, and ways to discover immune response modifiers derived from worms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available